PRESS RELEASES

Date	Title
Feb 17, 2017	Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
Feb 15, 2017	Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Jan 3, 2017	Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
Jan 3, 2017	Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
Nov 7, 2016	Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress
Oct 31, 2016	Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016
Oct 24, 2016	Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer
Oct 19, 2016	Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
Sep 22, 2016	Ardelyx to Present at Ladenburg Thalmann 2016 Healthcare Conference
Aug 15, 2016	Ardelyx to Present at Wedbush PacGrow Healthcare Conference

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com